pharmaceutical investing Acerus Updates on Temporary Unavailability of NATESTO in Canada and South Korea
pharmaceutical investing VIDEO - Acerus Pharma CEO: Keeping Focus on Drug Delivery Tech, Not Cannabis
Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor Application
NextSource Materials Signs Agreement for the Supply of Graphite Fines as Additional Source of Feedstock for its Battery Anode Facility in Abu Dhabi
